Citizens Maintains Market Outperform on Precigen, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 88.9%

Neg 0% Neu 0% Pos 88.9%

Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $8 to $9.